Lung factor

New publications:

 

Are physicians in primary health care able to recognize pulmonary fibrosis?

Purokivi M, Hodgson U, Myllärniemi M, Salomaa ER, Kaarteenaho R.
Eur Clin Respir J. 2017 Feb 20;4(1):1290339. doi: 10.1080/20018525.2017.1290339. eCollection 2017.

 °

Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.

Sköld CM, Bendstrup E, Myllärniemi M, Gudmundsson G, Sjåheim T, Hilberg O, Altraja A, Kaarteenaho R, Ferrara G.
J Intern Med. 2017 Feb;281(2):149-166. doi: 10.1111/joim.12571. Epub 2016 Nov 13. Review.

 °

End-of-life care of patients with idiopathic pulmonary fibrosis.

Rajala K, Lehto JT, Saarinen M, Sutinen E, Saarto T, Myllärniemi M.
BMC Palliat Care. 2016 Oct 12;15(1):85.

 °

Gremlin-1 Overexpression in Mouse Lung Reduces Silica-Induced Lymphocyte Recruitment – A Link to Idiopathic Pulmonary Fibrosis through Negative Correlation with CXCL10 Chemokine.

Koli K, Sutinen E, Rönty M, Rantakari P, Fortino V, Pulkkinen V, Greco D, Sipilä P, Myllärniemi M.
PLoS One. 2016 Jul 18;11(7):e0159010. doi: 10.1371/journal.pone.0159010. eCollection 2016.

 °

Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis.

Kaunisto J, Kelloniemi K, Sutinen E, Hodgson U, Piilonen A, Kaarteenaho R, Mäkitaro R, Purokivi M, Lappi-Blanco E, Saarelainen S, Kankaanranta H, Mursu A, Kanervisto M, Salomaa ER, Myllärniemi M.
BMC Pulm Med. 2015 Aug 19;15:92. doi: 10.1186/s12890-015-0074-3.

 °

Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries.

Bendstrup E, Hyldgaard C, Altraja A, Sjåheim T, Myllärniemi M, Gudmundsson G, Sköld M, Hilberg O.
Eur Clin Respir J. 2015 Jul 1;2. doi: 10.3402/ecrj.v2.28348. eCollection 2015.

 °

Overexpression of activin-A and -B in malignant mesothelioma – attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth.

Tamminen JA, Yin M, Rönty M, Sutinen E, Pasternack A, Ritvos O, Myllärniemi M, Koli K.
Exp Cell Res. 2015 Mar 1;332(1):102-15. doi: 10.1016/j.yexcr.2014.12.010. Epub 2014 Dec 31.

 °

Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine.

Myllärniemi M, Kaarteenaho R.
Eur Clin Respir J. 2015 Feb 10;2. doi: 10.3402/ecrj.v2.26385. eCollection 2015. Review.

 °

Upregulation of alveolar levels of activin B, but not activin A, in lungs of west highland white terriers with idiopathic pulmonary fibrosis and diffuse alveolar damage.

Lilja-Maula L, Syrjä P, Laurila HP, Sutinen E, Palviainen M, Ritvos O, Koli K, Rajamäki MM, Myllärniemi M.
J Comp Pathol. 2015 Feb-Apr;152(2-3):192-200. doi: 10.1016/j.jcpa.2014.11.006. Epub 2014 Dec 30.

 °

Upregulation of activin-B and follistatin in pulmonary fibrosis – a translational study using human biopsies and a specific inhibitor in mouse fibrosis models.

Myllärniemi M, Tikkanen J, Hulmi JJ, Pasternack A, Sutinen E, Rönty M, Leppäranta O, Ma H, Ritvos O, Koli K.
BMC Pulm Med. 2014 Nov 1;14:170. doi: 10.1186/1471-2466-14-170.

Now at Lung factor / News

Ethical board approval for the FikSu -study

The ethical board at the Helsinki University Central Hospital has […]

BMC Pulm Med classifies our work as highly accessed

Our systematic review on IPF epidemiology has been ranked as […]

Finnish update on IPF in Duodecim

In the latest issue of Duodecim,  Finnish researchers publish an […]

Follow us on Facebook

Are you interested in our research? Please like us on […]

Archive »